Scotiabank began coverage on shares of ARS Pharmaceuticals (NASDAQ:SPRY – Free Report) in a report released on Friday, ...

Fintel reports that on March 7, 2025, Scotiabank initiated coverage of ARS Pharmaceuticals (NasdaqGM:SPRY) with a Sector ...

The U.S. Food and Drug Administration approved the expanded use of ARS Pharmaceuticals' nasal spray for severe allergic ...

Scotiabank analyst Louise Chen initiated coverage of ARS Pharmaceuticals (SPRY) with an Outperform rating and $30 price target The firm says ...

The US Food and Drug Administration (FDA) has approved ARS Pharmaceuticals’ neffy 1mg (epinephrine nasal spray) for treating ...

The approval of neffy marks the first major advancement in epinephrine delivery for patients over four years of age in more ...

ARS Pharmaceuticals (SPRY) announced that the FDA has approved neffy 1 mg for the treatment of Type I Allergic Reactions, including ...

Neffy 1 mg is the “first significant innovation” for epinephrine delivery in small children aged 4 years and up in over 35 ...

Parents and pediatricians just gained one more tool to combat severe allergic reactions in young kids. San Diego-based ARS ...

ARS Pharmaceuticals’ (Nasdaq: SPRY) shares closed up 3.4% at $10.87 yesterday, after the company announced that the US Food ...

ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report)‘s stock had its “outperform” rating reiterated by analysts at William Blair in a research note issued to investors on Monday,RTT News reports.